151 related articles for article (PubMed ID: 37442648)
1. Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia.
Braga AGO; Barbosa Pagnano KB; Campioni MDP; Lopes ABP; Duarte GO; Metze K; Lorand-Metze I
Hematol Transfus Cell Ther; 2024; 46(3):268-272. PubMed ID: 37442648
[TBL] [Abstract][Full Text] [Related]
2. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
3. High Level of CD8
Kwaśnik P; Zaleska J; Link-Lenczowska D; Zawada M; Wysogląd H; Ochrem B; Bober G; Wasilewska E; Hus I; Szarejko M; Prejzner W; Grzybowska-Izydorczyk O; Klonowska-Szymczyk A; Mędraś E; Kiełbus M; Sacha T; Giannopoulos K
Cells; 2024 Apr; 13(8):. PubMed ID: 38667336
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia.
Fujioka Y; Sugiyama D; Matsumura I; Minami Y; Miura M; Atsuta Y; Ohtake S; Kiyoi H; Miyazaki Y; Nishikawa H; Takahashi N
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885012
[TBL] [Abstract][Full Text] [Related]
5. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
6. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
[TBL] [Abstract][Full Text] [Related]
7. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi N; Tauchi T; Kitamura K; Miyamura K; Saburi Y; Hatta Y; Miyata Y; Kobayashi S; Usuki K; Matsumura I; Minami Y; Usui N; Fukuda T; Takada S; Ishikawa M; Fujimaki K; Gomyo H; Sasaki O; Ohishi K; Miyake T; Imai K; Suzushima H; Mitsui H; Togitani K; Kiguchi T; Atsuta Y; Ohtake S; Ohnishi K; Kobayashi Y; Kiyoi H; Miyazaki Y; Naoe T;
Int J Hematol; 2018 Feb; 107(2):185-193. PubMed ID: 28929332
[TBL] [Abstract][Full Text] [Related]
8. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
10. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.
Mizoguchi I; Yoshimoto T; Katagiri S; Mizuguchi J; Tauchi T; Kimura Y; Inokuchi K; Ohyashiki JH; Ohyashiki K
Cancer Sci; 2013 Sep; 104(9):1146-53. PubMed ID: 23758044
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
12. MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Seguro FS; Maciel FVR; Santos FM; Abdo ANR; Pereira TDM; Nardinelli L; Rocha V; Bendit I
Leuk Res; 2021 Feb; 101():106516. PubMed ID: 33517185
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
Ohyashiki K; Umezu T; Katagiri S; Kobayashi C; Azuma K; Tauchi T; Okabe S; Fukuoka Y; Ohyashiki JH
Int J Mol Sci; 2016 Apr; 17(4):570. PubMed ID: 27092489
[TBL] [Abstract][Full Text] [Related]
14. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Marcé S; Méndez A; Xicoy B; Estrada N; Cabezón M; Sturla AL; García MR; Angona A; Amat P; Escribano Serrat S; Scalzulli E; Morgades M; Senín A; Hernández-Boluda JC; Ferrer-Marín F; Anguita E; Cortés M; Plensa E; Breccia M; García-Gutierrez V; Zamora L;
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337473
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML.
Millot F; Suttorp M; Ragot S; Leverger G; Dalle JH; Thomas C; Cheikh N; Nelken B; Poirée M; Plat G; Versluys B; Lausen B; Borisevich M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439257
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.
Goni D; Jain A; Singh C; Jindal N; Nampoothiri R; Jandial A; Lad D; Khadwal A; Prakash G; Naseem S; Varma N; Malhotra P
Indian J Med Res; 2023 Jan; 157(1):87-91. PubMed ID: 37040232
[TBL] [Abstract][Full Text] [Related]
17. Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.
Jun K; Ya-Zhen Q; Xiao-Su Z; Hong-Xia S; Yue-Yun L; Kai-Yan L; Xiao-Jun H; Hao J
Ther Adv Hematol; 2021; 12():2040620720986643. PubMed ID: 33613929
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
19. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.
Ohyashiki JH; Ohtsuki K; Mizoguchi I; Yoshimoto T; Katagiri S; Umezu T; Ohyashiki K
Drug Des Devel Ther; 2014; 8():1151-9. PubMed ID: 25187697
[TBL] [Abstract][Full Text] [Related]
20. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study.
Savaş EM; Yılmaz S; Başer Dikyar AA; Özkurt ZN; Öcal R; Can F; Pepeler S; Aydın Kaynar L; Gökçen S; Yıldız A; Albayrak M; Karakuş S; Çeneli Ö; Yağcı M
Turk J Haematol; 2023 Dec; 40(4):236-241. PubMed ID: 37877113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
